Michael A Posternak1, Mark Zimmerman. 1. Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 50 Staniford Street, Suite 4 01, Boston, MA 02114, USA. mposternak@partners.org
Abstract
BACKGROUND: It remains unclear how much various factors contribute to the placebo response. AIMS: To estimate the therapeutic impact of follow-up assessments on placebo response in antidepressant trials. METHOD: Double-blind, placebo-controlled antidepressant trials that reported weekly changes in Hamilton Rating Scale for Depression (HRSD) scores over 6 weeks were selected. Included studies (n=41) were divided into those that conducted four, five or six follow-up assessments. Reductions in HRSD scores as a function of the different follow-up schedules were compared. RESULTS: An extra follow-up visit at week 3 was associated with a 0.86 further reduction in HRSD score; an extra visit at week 5 was associated with a 0.67 further reduction. These effects represented approximately 34-44% of the placebo response that occurred over these time frames. Two additional visits were associated with twice the reduction in HRSD score than one, suggesting that the therapeutic impact of assessment visits is cumulative and proportional. A comparable therapeutic effect was also found in participants receiving active medication. CONCLUSIONS: Follow-up assessments in antidepressant treatment trials incur a significant therapeutic effect for participants on placebo, and this represents about 40% of the placebo response.
BACKGROUND: It remains unclear how much various factors contribute to the placebo response. AIMS: To estimate the therapeutic impact of follow-up assessments on placebo response in antidepressant trials. METHOD: Double-blind, placebo-controlled antidepressant trials that reported weekly changes in Hamilton Rating Scale for Depression (HRSD) scores over 6 weeks were selected. Included studies (n=41) were divided into those that conducted four, five or six follow-up assessments. Reductions in HRSD scores as a function of the different follow-up schedules were compared. RESULTS: An extra follow-up visit at week 3 was associated with a 0.86 further reduction in HRSD score; an extra visit at week 5 was associated with a 0.67 further reduction. These effects represented approximately 34-44% of the placebo response that occurred over these time frames. Two additional visits were associated with twice the reduction in HRSD score than one, suggesting that the therapeutic impact of assessment visits is cumulative and proportional. A comparable therapeutic effect was also found in participants receiving active medication. CONCLUSIONS: Follow-up assessments in antidepressant treatment trials incur a significant therapeutic effect for participants on placebo, and this represents about 40% of the placebo response.
Authors: Bret R Rutherford; Jane Tandler; Patrick J Brown; Joel R Sneed; Steven P Roose Journal: Am J Geriatr Psychiatry Date: 2013-11-05 Impact factor: 4.105
Authors: Emanuel Severus; Florian Seemüller; Michael Berger; Sandra Dittmann; Michael Obermeier; Andrea Pfennig; Michael Riedel; Sophia Frangou; Hans-Jürgen Möller; Michael Bauer Journal: BMC Med Date: 2012-07-02 Impact factor: 8.775
Authors: Richard A Hansen; Charity G Moore; Stacie B Dusetzina; Brian I Leinwand; Gerald Gartlehner; Bradley N Gaynes Journal: Med Decis Making Date: 2009-01-13 Impact factor: 2.583
Authors: Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Gitte M Knudsen; Julian Macoveanu; Allan R Hansen; Olaf B Paulson; Hartwig R Siebner; Lars V Kessing Journal: Trials Date: 2010-10-13 Impact factor: 2.279